Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928636 | 0.82 | DPP4 (0.39) | LMNAMEN1KMT2A | |
| SCHEMBL30135547 | 0.82 | DPP4 (0.39) | LMNAMEN1KMT2A | |
| SCHEMBL12649061 | 0.80 | TSHR (0.52) | TSHRALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL30135539 | 0.78 | EPHX2 (0.53) | EPHX2TSHRALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1843454 | 0.78 | KLK7 (0.45) | TSHRALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL29997863 | 0.78 | KLK7 (0.45) | TSHRALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL13997813 | 0.78 | KLK7 (0.45) | TSHRALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL28194949 | 0.78 | KLK7 (0.45) | TSHRALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL4412431 | 0.78 | L3MBTL1 (0.46) | TSHRALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL6528675 | 0.76 | ALDH1A1 (0.40) | TSHRALDH1A1LMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3 B Pharmaceuticals GmbH (DE) | 2024-10-10 | — | — | US | disclosed |
| EP-4373529-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| EP-4122499-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122499-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | FIBP, FGF2, FGFR2 | EPHX2 2786/4885TSHR 4085/4885ALDH1A1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.